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Obesity is a risk factor for breast cancer in postmenopausal women. In their recent article, Gunter et 
al. found that associations between breast cancer risk and circulating levels of adipokines were null 
to modest. Importantly, they underscored that adipokines primarily function in a paracrine manner. 
Hence, adipokine plasma levels might be a poor surrogate for breast tissue levels (1). This is 
reminiscent of the situation observed with vitamin D. Obesity is inversely associated with vitamin D 
levels (2), and vitamin D inadequacy is observed in postmenopausal women (2). Moreover, 1,25-
dihydroxyvitamin D (1,25D), the active metabolite of vitamin D, limits adipose tissue inflammation 
and suppresses leptin stimulation of cancer growth (3). As for adipokines, studies that have 
investigated the association between circulating levels of vitamin D and breast cancer risk gave 
mixed results (4,5). Could vitamin D and adipokines be two faces of the same coin?  
Vitamin D is barely active and requires two successive hydroxylations to produce 1,25D. The first 
hydroxylation is catalyzed in the liver by CYP2R1, the second one in the kidney by CYP27B1. This is 
the vitamin D endocrine system in which 1,25D is released in blood circulation and controls calcium 
homeostasis and skeletal health. Circulating 25(OH)-vitamin D levels between 50 and 75 nmol/L are 
considered indicative of vitamin D sufficiency.  
A paradigm shift recently occurred with the discovery of autocrine/paracrine vitamin D signaling in 
many tissues. In autocrine/paracrine systems, molecules are produced, act, and are degraded locally. 
Therefore, the autocrine/paracrine vitamin D signaling does not affect circulating levels of vitamin D 
metabolites. Two important features of the autocrine/paracrine vitamin D system are: 1) the 
regulation of CYP2R1 and CYP27B1 expression by inflammatory stimuli (6) and 2) the local storage of 
vitamin D in fat tissue (6). Hence, hydroxylated metabolites of vitamin D can be produced locally in 
response to inflammatory stimuli if sufficient local storage of vitamin D exists. Note that vitamin D 
storage in fat might require circulating levels of 25(OH)-vitamin D higher than 100 nmol/L (6). In 
other words, adequate functioning of the vitamin endocrine and autocrine/paracrine systems might 
require different vitamin D inputs. Shifting our thinking from endocrinology to paracrinology provides 
the missing link to unify in the same paradigm obesity, adipokines, vitamin D, inflammation, and 
cancer.  
In the autocrine/paracrine paradigm, adipokine-induced inflammation would promote the local 
expression of the vitamin D activating enzymes CYP2R1 and CYP27B1. This converts local vitamin D 
into its active metabolite 1,25D. This locally produced 1,25D would in turn control obesity-associated 
inflammation because of its anti-inflammatory potential.  
Adipokines and vitamin D can now be viewed as two faces of the same autocrine-paracrine signaling 
pathway whose dysfunction can participate in postmenopausal breast cancer risk. A necessary but 
not sufficient requirement of the system is the presence of adequate stores of vitamin D in breast fat 
tissue. For that reason, both local vitamin D and adipokine concentrations should be considered in 
addition to plasma levels. This provides a possible explanation for the mixed results obtained when 
plasma concentrations are used to investigate associations between adipokines or vitamin D and 
breast cancer risk.  
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